September 26, 2014
SOTIO, the biotechnology company owned by PPF Group, is presenting its clinical research program at the European Society for Medical Oncology’s 2014 Congress in Madrid (ESMO 2014). SOTIO’s exhibit can be found at booth no.107 in ESMO Exhibition Hall no. 8. Over the course of the ESMO Congress, SOTIO’s representatives will meet with important key opinion leaders (KOLs), researchers participating in company clinical trials and other medical and clinical experts.
The 39th ESMO Congress is taking place in Madrid from September 26thto 30th. More than 15,000 professionals from the fields of medical and surgical oncology, radiation oncology, immunology and pathology, are coming together to share ideas and new findings with the aim of further improving treatment options in solid tumors. The ESMO Congress is one of the two biggest scientific meetings in this field, together with the ASCO Annual Meeting (the American Society of Clinical Oncology).
About SOTIO clinical development:
SOTIO’s current focus is predominantly on a new Active Cellular Immunotherapy (ACI) for prostate cancer, called DCVAC/PCa. Five “Phase II” clinical trials are currently being carried out for this treatment. SOTIO commenced the “Phase III VIABLE” global clinical trial in May 2014, in order to verify the drug’s safety and efficacy. The company is undertaking clinical trials in European countries as well as in the US, with the goal of enrolling around 1,170 patients. In 2013, SOTIO also launched three “Phase II” clinical trials for a new ACI labelled DCVAC/OvCa for patients with ovarian cancer. These clinical trials are taking place in the Czech Republic, Germany and Poland. The company is also preparing to launch Phase I/II clinical trial for patients with lung cancer.